|1.||Ware, Mark A: 5 articles (04/2015 - 01/2006)|
|2.||Ethans, Karen: 3 articles (01/2015 - 02/2008)|
|3.||Maida, Vincent: 3 articles (03/2008 - 01/2007)|
|4.||Hill, Kevin P: 2 articles (06/2015 - 09/2014)|
|5.||Gomori, Andrew: 2 articles (01/2015 - 12/2009)|
|6.||Esfahani, Farid: 2 articles (01/2015 - 12/2009)|
|7.||Turcotte, Dana: 2 articles (01/2015 - 12/2009)|
|8.||Bedi, Gillinder: 2 articles (09/2013 - 07/2013)|
|9.||Haney, Margaret: 2 articles (09/2013 - 07/2013)|
|10.||Cooper, Ziva D: 2 articles (09/2013 - 07/2013)|
01/01/2006 - "Fifteen patients reported subjective overall improvement with nabilone, and nine reported reduced pain intensity. "
10/01/2006 - "To evaluate the safety and efficacy of low dose treatment with the synthetic cannabinoid Nabilone (1 mg per day) on spasticity-related pain a placebo-controlled double-blind crossover trial was performed.11 out of 13 included patients completed the study. "
01/01/2013 - "Following the starting of nabilone (a synthetic cannabinoid) his pain control was greatly improved and this had a huge impact on his quality of life. "
12/01/2000 - "Patients taking the synthetic derivative nabilone for neurogenic pain actually preferred cannabis herb and reported that it relieved not only pain but the associated depression and anxiety. "
01/01/2015 - "After adjustment for key patient-level covariates (e.g., age, sex, Expanded Disability Status Scale, duration of MS, baseline pain), a significant group × time(2) interaction term was reported for both the VASpain (P < 0.01) and VASimpact score (P < 0.01), demonstrating the adjusted rate of decrease for both outcomes was statistically greater in nabilone vs placebo study group. "
08/01/1985 - "The pharmacological profile of nabilone suggests that it acts primarily by preventing emesis controlled by the medulla oblongata, although its secondary mild anxiolytic activity may contribute to the overall efficacy. "
11/01/1983 - "Fewer subjects vomited with nabilone (P = 0.05) and the number of vomiting episodes was lower (P less than 0.05); no patients on nabilone required additional parenteral anti-emetic. "
01/01/2003 - "The cannabinoid nabilone is currently licensed for use as an antiemetic agent in chemotherapy-induced emesis. "
07/01/1984 - "Nabilone is a cannabinoid anti-emetic which has been extensively evaluated in control of chemotherapy-induced vomiting. "
12/01/1982 - "Use of nabilone in the treatment of chemotherapy-induced vomiting in an outpatient setting."
03/01/2008 - "Other ESAS parameters that improved significantly in patients receiving nabilone were nausea (P < 0.0001), anxiety (P = 0.0284) and overall distress (total ESAS score; P = 0.0208). "
03/01/2009 - "Nabilone, a synthetic derivative of Delta9-tetrahydrocannabinol (Delta9-THC), which is the main natural psychotropic constituent of C sativa, was approved by the US FDA for the treatment of nausea and as an anti-emetic for patients undergoing chemotherapy. "
01/01/2014 - "In this case report, we present 20-year-old woman who developed protracted nausea and vomiting secondary to cannabis withdrawal and was successfully treated with nabilone. "
01/01/2014 - "Nabilone therapy for cannabis withdrawal presenting as protracted nausea and vomiting."
02/01/2010 - "The most common AEs for nabilone were dizziness, nausea, and dry mouth. "
02/01/2008 - "Clinical trials have demonstrated the benefits of nabilone in cancer chemotherapy patients. "
12/01/1982 - "Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy."
06/01/1987 - "Nabilone appears to be a safe, effective, and well-tolerated antiemetic drug for children receiving cancer chemotherapy. "
05/01/1986 - "Nabilone: an alternative antiemetic for cancer chemotherapy."
08/01/1985 - "Thus, nabilone offers an effective alternative to the treatment options available in a difficult therapeutic area - those patients with severe gastrointestinal side effects from cancer chemotherapy who are refractory to conventional therapy."
|5.||Post-Traumatic Stress Disorders (PTSD)
01/01/2015 - "The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study."
01/01/2015 - "Investigate the efficacy of nabilone capsules (NAB) in reducing the frequency and intensity of nightmares in subjects with PTSD. "
01/01/2015 - "However, several failed clinical trials have diminished enthusiasm for the continued development of eCB-targeted therapeutics for psychiatric disorders, despite the encouraging preclinical data and promising preliminary results obtained with the synthetic cannabinoid nabilone for treating post-traumatic stress disorder. "
01/01/2009 - "The results of this study indicate the potential benefits of nabilone, a synthetic cannabinoid, in patients with PTSD experiencing poor control of nightmares with standard pharmacotherapy. "
01/01/2015 - "There is a need for further exploration of the effect of nabilone on other symptoms of PTSD such as re-experiencing, hyper vigilance and insomnia."
|6.||Cannabinoid Receptors (Cannabinoid Receptor)
|7.||Levodopa (L Dopa)
|1.||Drug Therapy (Chemotherapy)
|5.||Patient-Controlled Analgesia (Analgesia, Patient Controlled)